🚀 VC round data is live in beta, check it out!
ORIC Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for ORIC Pharmaceuticals and similar public comparables like Chongqing Genrix, Jubilant Pharmova, Iovance Biotherapeutics, Kodiak Sciences and more.
ORIC Pharmaceuticals Overview
About ORIC Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Founded
2014
HQ
Employees
104
Website
Sectors
Financials (LTM)
EV
$1B
ORIC Pharmaceuticals Financials
ORIC Pharmaceuticals reported last 12-month revenue of — and negative EBITDA of ($145M).
In the same LTM period, ORIC Pharmaceuticals generated — in gross profit, ($145M) in EBITDA losses, and had net loss of ($133M).
Revenue (LTM)
ORIC Pharmaceuticals P&L
In the most recent fiscal year, ORIC Pharmaceuticals reported revenue of — and EBITDA of ($142M).
ORIC Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($145M) | XXX | ($142M) | XXX | XXX | XXX |
| Net Profit | ($133M) | XXX | ($129M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ORIC Pharmaceuticals Stock Performance
ORIC Pharmaceuticals has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
ORIC Pharmaceuticals' stock price is $13.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-1.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialORIC Pharmaceuticals Valuation Multiples
ORIC Pharmaceuticals trades at (8.5x) EV/EBITDA.
ORIC Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, ORIC Pharmaceuticals has market cap of $2B and EV of $1B.
Equity research analysts estimate ORIC Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ORIC Pharmaceuticals has a P/E ratio of (11.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | (8.5x) | XXX | (8.7x) | XXX | XXX | XXX |
| EV/EBIT | (8.4x) | XXX | (8.6x) | XXX | XXX | XXX |
| P/E | (11.4x) | XXX | (11.7x) | XXX | XXX | XXX |
| EV/FCF | (11.4x) | XXX | (11.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ORIC Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ORIC Pharmaceuticals Margins & Growth Rates
ORIC Pharmaceuticals' revenue in the last fiscal year grew by —.
ORIC Pharmaceuticals' revenue per employee in the last FY averaged $0.0M.
ORIC Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ORIC Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Iovance Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kodiak Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vir Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ORIC Pharmaceuticals M&A Activity
ORIC Pharmaceuticals acquired XXX companies to date.
Last acquisition by ORIC Pharmaceuticals was on XXXXXXXX, XXXXX. ORIC Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ORIC Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialORIC Pharmaceuticals Investment Activity
ORIC Pharmaceuticals invested in XXX companies to date.
ORIC Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. ORIC Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ORIC Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ORIC Pharmaceuticals
| When was ORIC Pharmaceuticals founded? | ORIC Pharmaceuticals was founded in 2014. |
| Where is ORIC Pharmaceuticals headquartered? | ORIC Pharmaceuticals is headquartered in United States. |
| How many employees does ORIC Pharmaceuticals have? | As of today, ORIC Pharmaceuticals has over 104 employees. |
| Who is the CEO of ORIC Pharmaceuticals? | ORIC Pharmaceuticals' CEO is Jacob M. Chacko. |
| Is ORIC Pharmaceuticals publicly listed? | Yes, ORIC Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of ORIC Pharmaceuticals? | ORIC Pharmaceuticals trades under ORIC ticker. |
| When did ORIC Pharmaceuticals go public? | ORIC Pharmaceuticals went public in 2020. |
| Who are competitors of ORIC Pharmaceuticals? | ORIC Pharmaceuticals main competitors are Chongqing Genrix, Jubilant Pharmova, Iovance Biotherapeutics, Kodiak Sciences. |
| What is the current market cap of ORIC Pharmaceuticals? | ORIC Pharmaceuticals' current market cap is $2B. |
| Is ORIC Pharmaceuticals profitable? | No, ORIC Pharmaceuticals is not profitable. |
| What is the current EBITDA of ORIC Pharmaceuticals? | ORIC Pharmaceuticals has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of ORIC Pharmaceuticals? | Current EBITDA multiple of ORIC Pharmaceuticals is (8.5x). |
| What is the current FCF of ORIC Pharmaceuticals? | ORIC Pharmaceuticals' last 12 months FCF is ($108M). |
| What is the current EV/FCF multiple of ORIC Pharmaceuticals? | Current FCF multiple of ORIC Pharmaceuticals is (11.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.